Gossamer Bio, Inc. (NASDAQ:GOSS) Shares Sold by Jacobs Levy Equity Management Inc.

Jacobs Levy Equity Management Inc. lowered its position in shares of Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) by 18.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,534,668 shares of the company's stock after selling 352,844 shares during the quarter. Jacobs Levy Equity Management Inc. owned approximately 0.68% of Gossamer Bio worth $1,388,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Charles Schwab Investment Management Inc. lifted its position in Gossamer Bio by 1.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,241,979 shares of the company's stock worth $1,123,000 after buying an additional 13,902 shares during the period. Silverarc Capital Management LLC boosted its position in shares of Gossamer Bio by 9.3% in the fourth quarter. Silverarc Capital Management LLC now owns 6,171,847 shares of the company's stock worth $5,583,000 after acquiring an additional 526,495 shares during the last quarter. Allostery Investments LP purchased a new stake in Gossamer Bio in the fourth quarter valued at approximately $555,000. Alyeska Investment Group L.P. grew its holdings in Gossamer Bio by 52.7% in the fourth quarter. Alyeska Investment Group L.P. now owns 8,808,514 shares of the company's stock valued at $7,968,000 after purchasing an additional 3,041,058 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in Gossamer Bio by 1.7% in the fourth quarter. Geode Capital Management LLC now owns 2,250,461 shares of the company's stock valued at $2,037,000 after acquiring an additional 38,084 shares during the last quarter. 81.23% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

GOSS has been the topic of several recent research reports. The Goldman Sachs Group lifted their target price on shares of Gossamer Bio from $7.00 to $8.00 and gave the company a "buy" rating in a report on Friday. HC Wainwright reaffirmed a "buy" rating and issued a $10.00 target price on shares of Gossamer Bio in a research report on Tuesday, March 18th. Finally, Wedbush reissued an "outperform" rating and set a $4.00 price target on shares of Gossamer Bio in a research report on Friday.

Gossamer Bio Stock Up 8.3%

Shares of NASDAQ:GOSS traded up $0.09 during trading on Tuesday, hitting $1.18. The company's stock had a trading volume of 2,330,997 shares, compared to its average volume of 1,534,697. The company has a market capitalization of $268.12 million, a PE ratio of -3.69 and a beta of 1.82. The company has a debt-to-equity ratio of 3.64, a quick ratio of 6.74 and a current ratio of 6.74. The stock's 50-day moving average price is $1.04 and its two-hundred day moving average price is $0.99. Gossamer Bio, Inc. has a fifty-two week low of $0.50 and a fifty-two week high of $1.55.

Gossamer Bio (NASDAQ:GOSS - Get Free Report) last released its earnings results on Thursday, May 15th. The company reported ($0.16) EPS for the quarter, topping analysts' consensus estimates of ($0.18) by $0.02. The firm had revenue of $9.89 million for the quarter, compared to the consensus estimate of $3.95 million. As a group, sell-side analysts expect that Gossamer Bio, Inc. will post -0.28 EPS for the current year.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.